Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF

Not Applicable

• Conditions: Heart Failure With Preserved Ejection Fraction
• Interventions: Device: Satera GSN Ablation; Device: Sham Control

• Registration Number: NCT04592445
• Lead Sponsor: Axon Therapies, Inc.

Brief Summary

The objective of this clinical evaluation is to assess the safety and initial effectiveness of catheter-based unilateral ablation of the right greater splanchnic nerve (GSN) in subjects having heart failure with preserved ejection fraction (HFpEF).

Detailed Description

This clinical investigation is a prospective, multi-center randomized, sham control, double blinded feasibility clinical study. Both the subject and the noninvasive cardiologist that is caring for the subject will be blinded to the assigned cohort (treatment or sham). The interventional cardiologist who performs the index procedure will not be blinded.

Subjects who meet the eligibility criteria and are enrolled will be randomized 1:1 to either ablation of the right GSN using the Axon System (treatment cohort) or sham (control cohort) at the time of the procedure.

This study will enroll up to 100 subjects at an anticipated 20 US sites. Subject follow up is at 1, 3, 6, and 12 months

Study Timeline

• Study First Submitted: 2020-10-07
• Study First Submitted QC: 2020-10-13
• Study First Posted: 2020-10-19
• Study Start: 2020-12-18
• Status Verified: 2021-12
• Last Update Submitted: 2021-12-14
• Last Update Posted: 2022-01-04
• Primary Completion: 2022-04
• Study Completion: 2023-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Subjects ≥ 40 years of age

2. Chronic heart failure defined as at least one of the following:

   1. Symptoms of HF requiring current treatment with diuretics (intermittent or continuous) for > 30 days, AND

   2. NYHA class II with a history of > NYHA class II in the past year, NYHA class III, or ambulatory NYHA class IV symptoms (paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate exertion) at screening; or signs of HF (any rales post cough, chest x-ray demonstrating pulmonary congestion), AND

   3. > 1 HF hospital admission (with HF as the primary, or secondary diagnosis);

      • OR - treatment with intravenous (IV) diuretics, or intensification of oral diuresis for HF in a healthcare facility within the 12 months prior to study entry;
      • OR - NT-pro BNP value > 150 pg/ml in normal sinus rhythm, > 450 pg/ml in atrial fibrillation within the past 6 months;
      • OR - BNP value > 50 pg/ml in normal sinus rhythm, > 150 pg/ml in atrial fibrillation within the past 6 months.

3. Ongoing stable GDMT HF management (unless unable to tolerate GDMT) and management of potential comorbidities according to the 2017 ACCF/AHA Guideline for the Management of Heart Failure, with no significant changes [>100% increase or 50% decrease] for a minimum of 1 month prior to screening, that is expected to be maintained without change for at least 3 months.

4. LVEF ≥ 50 % (site determined by TTE) in the past 3 months.

5. Site determined elevated PCWP documented by right heart catheterization by PCWP ≥ 25 mmHg during supine ergometer exercise

   a. PCWP to be evaluated by a Swan Ganz procedure performed either prior to the day of the index procedure or on the day of the index procedure

6. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.

Exclusion Criteria

1. MI (type I) and/or percutaneous cardiac intervention within past 3 months; CABG in past 3 months, or current indication for coronary revascularization.

2. Cardiac Resynchronization Therapy initiated within the past 3 months prior to screening.

3. Advanced heart failure defined as one or more of the below:

   1. ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF
   2. Cardiac index < 2.0 L/min/m2
   3. Inotropic infusion (continuous or intermittent) for LV EF< 30% within the past 6 months prior to screening
   4. Subject is on the cardiac transplant waiting list

4. BMI > 45 kg/m2

5. Inability to perform 6-minute walk test (distance < 100 meters), OR ability to perform 6-minute walk test distance > 450 meters.

6. Admission for HF within the 30 days prior to planned index procedure.

7. In the last 3 years an ejection fraction (EF) below 40

8. Systolic BP < 100 mmHg or > 170 mmHg despite appropriate medical management.

9. Symptomatic orthostatic hypotension or orthostatic hypotension requiring treatment (orthostatic hypotension is defined as systolic blood pressure decrease of >20mmHg and/or increase in heart rate >20 bpm upon going from supine to standing position).

10. Arterial oxygen saturation < 90 % on room air.

11. Presence of significant valve disease defined by the site cardiologist as:

    1. Mitral valve stenosis defined as <1.5 cm2 (or greater than mild)
    2. Mitral valve regurgitation defined as grade > 3+ MR
    3. Tricuspid valve regurgitation defined as grade > 3+ TR
    4. Aortic valve disease defined as > 3+ AR or > severe AS

12. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or other infiltrative cardiomyopathy (e.g., hemochromatosis, sarcoidosis)

13. Vessel tortuosity or variant vascular anatomy that could preclude the access or maneuvering of the interventional device from the access site to target vessel. This includes previous spine surgery that may impact the ability to access and treat the target sites of T11 and T10.

14. Mean resting right atrial pressure (RAP) > 20 mmHg based upon screening right heart catheterization.

15. History of severe liver cirrhosis

16. Dialysis dependent; or estimated-GFR <25 ml/min/1.73 m2 by MDRD equation.

17. Baseline status of persistent atrial fibrillation with resting HR >100 beats per minute that could obfuscate RHC interpretation.

18. Chronic pulmonary disease requiring continuous home oxygen OR hospitalization for exacerbation (including intubations) in the 12 months before study entry OR known history of GOLD Class II or higher COPD.

19. Currently participating in conflicting investigational drug or device study.

20. Life expectancy <12 months for non-cardiovascular reasons.

21. Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient.

22. Females who are not pregnant or lactating and not or planning to become pregnant for the duration of the study during the next year.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Axon Treatment Arm	Satera GSN Ablation	Subjects will receive treatment with the Satera Ablation System following administration of anesthesia access to the R GSN and ablation of the GSN at 1-2 levels will occur.
Sham Control Arm	Sham Control	Following administration of anesthesia subjects will have femoral vein access only. Procedure choreography to mimic procedure steps and length.

Primary Outcome Measures

Name	Time	Method
Primary Safety Outcome	1 month	Evaluation of device or procedure-related serious adverse events at 1-month follow up based on Clinical Events Committee (CEC) assessment.
Primary Outcome Endpoint	1 Month	Change in mean PCWP at 1 month follow up evaluated as a repeated measure at rest, legs up and exercise (20W) as compared to the baseline PCWP evaluation. This reduction will be assessed in all subjects (both treated and control) to explore mechanism of action

Secondary Outcome Measures

Name	Time	Method
Secondary Outcome Endpoints	1 month	\*Reduction in PCWP at 1 month follow up at rest, legs up, exercise at 20W and peak exercise as compared to the baseline PCWP evaluation.

Trial Locations

Locations (17)

Bluhm Cardiovascular Institute of Northwestern University; 🇺🇸 Chicago, Illinois, United States

Cardiology PC; 🇺🇸 Birmingham, Alabama, United States

Arizona Cardiovascular Research Center; 🇺🇸 Phoenix, Arizona, United States

University of California, San Francisco; 🇺🇸 San Francisco, California, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Scripps Health; 🇺🇸 La Jolla, California, United States

University of Chicago Medical Center; 🇺🇸 Chicago, Illinois, United States

Cardiovascular Institute of the South; 🇺🇸 Houma, Louisiana, United States

Prairie Education and Research Cooperative; 🇺🇸 Springfield, Illinois, United States

Center for Advanced Cardiac Care, Columbia University Medical Center; 🇺🇸 New York, New York, United States

Weill Cornell Medicine; 🇺🇸 New York, New York, United States

Icahn School of Medicine at Mount Sinai; 🇺🇸 New York, New York, United States

Ohio State University Wexner Medical Center; 🇺🇸 Columbus, Ohio, United States

Michigan Medicine, University of Michigan; 🇺🇸 Ann Arbor, Michigan, United States

Medical University of South Carolina, Gazes Cardiac Research Institute; 🇺🇸 Charleston, South Carolina, United States

Virginia Commonwealth University Medical Center; 🇺🇸 Richmond, Virginia, United States